Mark W. Hahn - 18 May 2026 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Reporting relationship: Director
Issuer ticker: SLNO
Reported as of: 18 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 May 2026, 16:34:41 UTC
Prior SEC filing: 14 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Anish Bhatnagar, Attorney-in-Fact

Key filing fact

Mark W. Hahn filed Form 4 for SOLENO THERAPEUTICS INC (SLNO) on 18 May 2026.

Key facts

This page summarizes Mark W. Hahn's Form 4 filing for SOLENO THERAPEUTICS INC (SLNO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 May 2026, 16:34.

Change

Previous filing in this sequence was filed on 14 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001408502 Primary reporting owner

Hahn Mark W

Relationship: Director
Address: 100 MARINE PARKWAY, SUITE 400, REDWOOD CITY
Signature: /s/ Anish Bhatnagar, Attorney-in-Fact
Signature date: 18 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLNO transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -10,046
Change %: -100%
Price
Shares after: 0
Date: 18 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Mark W. Hahn is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

These shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration").